Is ensidipine a drug reimbursed by medical insurance?

Ensidipine, trade nameIDHIFA, is an innovative drug specifically targeted at acute myeloid leukemia (AML), especially for patients with isocitrate dehydrogenase 2 (IDH2) gene mutations. Ensidipine, with its unique mechanism, has opened up new avenues in the field of AML treatment. As an oral, specific and selective IDH2 inhibitor, it can precisely inhibit the activity of mutated IDH2 enzyme, thereby inhibiting the production of the abnormal metabolite 2-hydroxyglutarate (2-HG). Through this mechanism, ensidipine promotes normal cell differentiation, inhibits the proliferation of leukemia cells, and can even induce these abnormal cells to undergo apoptosis.

Clinical trial data fully demonstrate the efficacy of ensidipine. In trials of AML patients with IDH2 mutations, ensidipine not only achieved a 23% complete response rate with partial hematological improvement, but also achieved a median response duration of 8.2 months. This result is undoubtedly exciting news for this patient group.

In terms of safety, although ensidipine may cause some common adverse reactions, such as nausea, diarrhea, or loss of appetite, these symptoms can usually be relieved with appropriate medical management. Additionally, this drug is contraindicated in pregnant women as it may cause harm to the fetus.

Encidipine is not currently on the market in the country, so it cannot be included in medical insurance reimbursement items. Patients who need this medicine can only purchase it from overseas or contact formal overseas medical consulting companies for information. It is understood that generic drugs of ensidipine are already on the market overseas, such as the versions produced by Ziskar Pharmaceuticals of Bangladesh and Lucius Pharmaceuticals of Laos. The price of 30 tablets is about more than 2,000 yuan. Patients who have more questions about ensidipine can consult professional overseas medical consulting companies.

In summary, ensidipine, with its unique targeting and significant efficacy in clinical trials, is a promising candidate forAML patients with IDH2 mutations bring new treatment options and hope.